

Product datasheet

Recombinant Human PPP1R3B protein (denatured) ab171709

1 Image

Description

Product name	Recombinant Human PPP1R3B protein (denatured)	
Purity	> 85 % SDS-PAGE.	
Expression system Accession Protein length Animal free Nature Species	Escherichia coli Q86XI6 Full length protein No Recombinant Human	
Sequence		MGSSHHHHHHSSGLVPRGSHMGSMMAVDIEYRYNCMAP SLRQERFAFKIS PKPSKPLRPCIQLSSKNEASGMVAPAVQEKKVKKRVSFA DNQGLALTMVK VFSEFDDPLDMPFNITELLDNIVSLTTAESESFVLDFSQPS ADYLDFRNR LQADHVCLENCVLKDKAIAGTVKVQNLAFEKTVKIRMTFD TWKSYTDFPC QYVKDTYAGSDRDTFSFDISLPEKIQSYERMEFAVYYECN GQTYWDSNRG KNYRIIRAELKSTQGMTKPHSGPDLGISFDQFGSPRCSYGL FPEWPSYLG YEKLGPYY
Predicted molecular weight	35 kDa including tags	
Amino acids	1 to 285	
Tags	His tag N-Terminus	
Description	Recombinant Human PPP1R3B protein	


Specifications

Our <u>Abpromise guarantee</u> covers the use of ab171709 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Applications	SDS-PAGE	
Form	Liquid	
Preparation and Storage		
Stability and Storage	Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or - 80°C. Avoid freeze / thaw cycle.	
	pH: 8.00 Constituents: 2.4% Urea, 0.32% Tris HCl, 10% Glycerol (glycerin, glycerine)	
General Info		
Function	Acts as a glycogen-targeting subunit for phosphatase PP1. Facilitates interaction of the PP1 with enzymes of the glycogen metabolism and regulates its activity. Suppresses the rate at which PP1 dephosphorylates (inactivates) glycogen phosphorylase and enhances the rate at which it activates glycogen synthase and therefore limits glycogen breakdown. Its activity is inhibited by PYGL, resulting in inhibition of the glycogen synthase and glycogen phosphorylase phosphatase activities of PP1. Dramatically increases basal and insulin-stimulated glycogen synthesis upon overexpression in hepatocytes.	
Tissue specificity	Highly expressed in liver. Expressed moderately in skeletal muscle and myotubes (at protein level). Expressed predominantly in heart and skeletal muscle. Expressed moderately in liver. Expressed weakly in placenta, lung and kidney.	
Sequence similarities	Contains 1 CBM21 (carbohydrate binding type-21) domain.	
Domain	The N-terminal region is required for binding to PP1, the central region is required for binding to glycogen and the C-terminal region is required for binding to PYGL.	





15% SDS-PAGE analysis of ab171709 (3µg).

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <u>https://www.abcam.com/abpromise</u> or contact our technical team.

Terms and conditions

• Guarantee only valid for products bought direct from Abcam or one of our authorized distributors